Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Josh Bittker"'
Autor:
Li Wang, Jeff Settleman, Mustafa Kocak, Aaron Boudreau, David Stokoe, Amy Goodale, James Rong, Jordan Byran, Fiona E. McAllister, Josh Bittker, Todd R. Golub, Cong Zhu, Ari J. Firestone, Daphne Koller, Jordan Rossen, Kevin Larpenteur, Nicholas Eriksson, Samantha Bender, Aviad Tsherniak, Christopher C. Mader, Niclas Olsson, Colin Trepicchio, Aravind Subramanian, Jennifer Roth, Frank Li, Federica Piccioni
Publikováno v:
Molecular Cancer Therapeutics. 18:B121-B121
KEAP1-mutant non-small cell lung cancer is a high prevalence indication that responds poorly to conventional chemotherapy owing to constitutive activation of NRF2 and its associated drug metabolism target genes. Using an approach to identify compound
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a91fb2e9cdec1f3ef9b0f0d04b4adf62
https://doi.org/10.1158/1535-7163.targ-19-b121
https://doi.org/10.1158/1535-7163.targ-19-b121
Autor:
James M. McFarland, Samantha Bender, David Stokoe, Lucian de Waal, Jordan Bryan, Ari J. Firestone, Colin Trepiccio, Federica Piccioni, David E. Root, Li Wang, Michael V. Rothberg, Kevin Larpenteur, Matt Kukurugya, Christopher C. Mader, Amy Goodale, Jennifer Roth, Bryson Bennett, Brenton R. Paolella, Sulyman Barkho, Josh Bittker, Min Cho, Aviad Tsherniak, Mustafa Kocak, Todd R. Golub, Cong Zhu, James Rong
Publikováno v:
Molecular Cancer Therapeutics. 18:C022-C022
A comprehensive analysis of FDA approved drugs has shown that drug discovery through phenotypic screening yields a higher percentage of first-in-class compounds, compared to canonical target-based drug discovery. This has led to a renewed interest in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::392c85747bde088091c15122237dea8b
https://doi.org/10.1158/1535-7163.targ-19-c022
https://doi.org/10.1158/1535-7163.targ-19-c022